On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.
Jonathan Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Bœuf, Derek R. Clements, Jean‐Eudes Fahrner, Laetitia Fend, John C. Bell, Karen Mossman, Jitka Fučíková, Radek Špíšek, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi
Stephanie Blake, Pascale Guitera, Anne Ε. Cust, Claire Galea, Serigne Lo, Richard A Scolyer, Bruce K. Armstrong, John F. Thompson, Scott W. Menzies, Christine Madronio, Rachael L. Morton, Graham J. Mann, Caroline G. Watts
Discussion(0)
No comments yet. Be the first to comment.